Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma

Published:2017-06-27 Issue:6 Volume:178 Page:936-948
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Bernasconi Elena¹,Gaudio Eugenio¹^ORCID,Lejeune Pascale²,Tarantelli Chiara¹,Cascione Luciano¹³^ORCID,Kwee Ivo¹⁴⁵,Spriano Filippo¹,Rinaldi Andrea¹,Mensah Afua A.¹,Chung Elaine¹,Stathis Anastasios³,Siegel Stephan²,Schmees Norbert²,Ocker Matthias³,Zucca Emanuele⁴,Haendler Bernard²,Bertoni Francesco¹³^ORCID

Affiliation:

1. Università della Svizzera italiana (USI); Institute of Oncology Research (IOR); Bellinzona Switzerland

2. Drug Discovery; Bayer AG; Berlin Germany

3. Oncology Institute of Southern Switzerland (IOSI); Bellinzona Switzerland

4. IDSIA Dalle Molle Institute for Artificial Intelligence; Manno Switzerland

5. SIB Swiss Institute of Bioinformatics; Lausanne Switzerland

Funder

Bayer

Gelu Foundation

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.14803/fullpdf

Reference45 articles.

1. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study;Amorim;The Lancet Haematology,2016

2. Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study;Berthon;The Lancet Haematology,2016

3. BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma;Bhadury;Proceedings of the National Academy of Sciences of the United States of America,2014

4. PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma;Boi;Blood,2013

5. The BET bromodomain inhibitor OTX015 affects pathogenetic pathways in preclinical B-cell tumor models and synergizes with targeted drugs;Boi;Clinical Cancer Research,2015

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy;Signal Transduction and Targeted Therapy;2023-11-06

2. Targeting the epigenetic reader “BET” as a therapeutic strategy for cancer;Bioorganic Chemistry;2023-11

3. Targeting epigenetic regulation for cancer therapy using small molecule inhibitors;Advances in Cancer Research;2023

4. Evaluation of the Synergistic Potential of Simultaneous Pan- or Isoform-Specific BET and SYK Inhibition in B-Cell Lymphoma: An In Vitro Approach;Cancers;2022-09-27

5. Roles of Bromodomain Extra Terminal Proteins in Metabolic Signaling and Diseases;Pharmaceuticals;2022-08-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3